The recognition that neurodegenerative diseases often involve complex combinations of protein pathologies—including tau, TDP-43, amyloid β, and α-synuclein—sometimes alongside cerebrovascular disease,5,22,23,111 has driven a paradigm shift in their clinical characterisation. This evidence concerns the gene TARDBP and neurodegenerative disease.